Exploration of Postoperative Follow-up Strategies for Early Staged NSCLC Patients on the Basis of Follow-up Result of 416 Stage I NSCLC Patients after Lobectomy.
10.3779/j.issn.1009-3419.2018.03.15
- Author:
Liang DAI
1
;
Wanpu YAN
1
;
Xiaozheng KANG
1
;
Hao FU
1
;
Yongbo YANG
1
;
Haitao ZHOU
1
;
Zhen LIANG
1
;
Hongchao XIONG
1
;
Yao LIN
1
;
Keneng CHEN
1
Author Information
1. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), the First Department of Thoracic Surgery,
Peking University Cancer Hospital and Institute, Peking University School of Oncology, Beijing 100142, China.
- Publication Type:Journal Article
- Keywords:
Follow-up;
Lobectomy;
Lung neoplasms;
Prognosis
- MeSH:
Adolescent;
Adult;
Aged;
Aged, 80 and over;
Carcinoma, Non-Small-Cell Lung;
mortality;
pathology;
surgery;
Female;
Follow-Up Studies;
Humans;
Lung Neoplasms;
mortality;
pathology;
surgery;
Lymph Nodes;
surgery;
Lymphatic Metastasis;
Male;
Middle Aged;
Neoplasm Staging;
Pneumonectomy;
Prospective Studies;
Retrospective Studies;
Young Adult
- From:
Chinese Journal of Lung Cancer
2018;21(3):199-203
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:Currently, there is no consensus on the follow-up strategy (follow-up time interval and content) of non-small cell lung cancer (NSCLC) in the world, and the relevant clinical evidence is also very limited. In this study, we aimed to summarize the recurrence/metastasis sites and timings of stage I NSCLC patients based on their follow-up data, aiming to provide a basis of follow-up time interval and content for this group of patients.
METHODS:We retrospectively analyzed the 416 stage I NSCLC patients that underwent continuous anatomic lobectomy between Jan. 2000 to Oct. 2013 in our prospective lung cancer database. According to the recurrence/metastasis sites and timings, the long term follow-up time interval and content were explored.
RESULTS:The 5-yr disease free survival (DFS) and overall survival (OS) in the whole group were 82.4% and 85.4%, respectively. There were 76 cases (18.3%) had recurrence/metastasis during follow-up, among which the most frequent site was pulmonary metastasis (21 cases, 5.0%), followed by brain metastasis (20 cases, 4.8%), bone metastasis (12 cases, 2.9%), and mediastinal lymph node metastasis (12 cases, 2.9%). Among the factors that could influence recurrence/metastasis, patients with pT2a suffered from a higher recurrence/metastasis rate compared to patients with pT1 (P=0.006), with 5-yr DFS being 73.8% and 87.3%, respectively (P=0.002), and the 5-yr OS being 77.7% and 90.3%, respectively (P=0.011).
CONCLUSIONS:The commonest recurrence/metastasis sites of stage I NSCLC after anatomic lobectomy are lung, brain and mediastinal lymph nodes, the risk of recurrence/metastasis within 2 years were equal to that between 3 years and 5 years. The follow-up frequencies and content within 2 years could be adjusted according to T stages.
